This issue of the UFHCC Connection highlights clinical trials currently recruiting patients with neuro-related cancers.
Questions about how to send a patient? Please contact the Clinical Trials Office at firstname.lastname@example.org or 352.273.8675
Recurrent Brain Metastasis Immune Effects and RespOnse to Laser Interstitial ThermotHerapy (LITT) and Pembrolizumab in Combination (TORCH)
The purpose of this research study is to determine if laser interstitial thermotherapy (LITT) plus pembrolizumab is effective in treatment of brain metastases that recur after stereotactic radiosurgery.
This is currently the only clinical trial for brain mets using novel therapies including laser ablation and immunotherapy.
This is a pilot study seeking 15 patients for enrollment at the University of Florida. All study patients will receive both LITT and pembrolizumab.
Subject inclusion criteria:
- Primary Melanoma, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Head and Neck Squamous Cell Cancer, Classical Hodgkin Lymphoma, Primary Mediastinal Large B-Cell Lymphoma, Urothelial Carcinoma, Microsatellite Instability-High Cancer, Gastric Cancer, Esophageal Cancer, Cervical Cancer, Hepatocellular Carcinoma, Merkel Cell Carcinoma, or Renal Cell Carcinoma
- Imaging demonstrating metastases (1-3 lesions) where at least one lesion has had prior stereotactic radiosurgery and demonstrates tumor growth
- 18 years or older
- No active viral or autoimmune disease
Principal Investigator: Maryam Rahman, M.D.
For information on this trial, please contact the TORCH clinical research coordinator:
Annie Allen, MBA | 352.294.8836 | email@example.com